Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

For $10 billion, Merck is acquiring a promising healthcare company which is in the early stages of its growth. Key to its ...

President Donald Trump said his administration has been holding talks with Harvard University and may announce a deal over the next week, potentially ending a standoff that has jeopardized ...

A version of this article appears in print on July 1, 2025, Section A, Page 9 of the New York edition with the headline: As Trade Deadline With U.S. Nears, Europe Reaches for Outline of Deal.

Vinay Prasad overruled other reviewers for a third time in recent months in clearing only narrow use of Moderna's vaccine in ...

An influenza vaccine candidate from Moderna showed promising results in a late-stage trial, bringing the drug maker one step closer to producing a combined flu-and-Covid shot.

The phase three study data clears the path forward for Moderna’s combination jab targeting Covid-19 and influenza.

Moderna (NASDAQ: MRNA), on Monday, reported positive results from a late-stage study comparing its influenza vaccine candidate, mRNA-1010, to a standard vaccine in adults aged 50 and older.

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the company’s mRNA-1010 flu vaccine’s efficacy was nearly 27 percent ...

Recent discussions on X about Moderna, Inc. (MRNA) have been buzzing with excitement following the company's announcement of positive late-stage trial results for its experimental mRNA-based ...

To tackle this challenge, researchers propose an investment fund that finances half the cost of an adaptive platform trial in exchange for future royalties from successful drugs that emerge from ...